Literature DB >> 27732828

Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma.

Parameswaran Hari1, Renju V Raj1, Horatiu Olteanu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27732828     DOI： 10.1056/NEJMc1605684

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  32 in total

1.  Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.

Authors:  Abraham S Kanate; Alyssa DiGilio; Kwang W Ahn; Monzr Al Malki; Eric Jacobsen; Amir Steinberg; Nelson Hamerschlak; Mohamed Kharfan-Dabaja; Rachel Salit; Edward Ball; Qaiser Bashir; Amanda Cashen; Daniel Couriel; Jose Diez-Martin; Emmanuel Katsanis; Yulia Linhares; Shahram Mori; Richard Nash; Attaphol Pawarode; Miguel-Angel Perales; Colin D Phipps; Carol Richman; Bipin N Savani; Michael Y Shapira; Patrick Stiff; Roger Strair; Timothy S Fenske; Sonali M Smith; Anna Sureda; Horatiu Olteanu; Mehdi Hamadani
Journal:  Br J Haematol       Date:  2017-08-02       Impact factor: 6.998

2.  CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.

Authors:  Meisam Naeimi Kararoudi; Yuya Nagai; Ezgi Elmas; Marcelo de Souza Fernandes Pereira; Syed Abbas Ali; Philip Hollingsworth Imus; Darren Wethington; Ivan Marques Borrello; Dean Anthony Lee; Gabriel Ghiaur
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

Review 3.  An Update on the Use of Immunotherapy in the Treatment of Lymphoma.

Authors:  Thomas U Marron; Matko Kalac; Joshua Brody
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

4.  Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.

Authors:  Paola Ghione; Shunan Qi; Brandon S Imber; Venkatraman Seshan; Alison Moskowitz; Natasha Galasso; Matthew Lunning; David Straus; Craig Sauter; Parastoo Dahi; Ahmet Dogan; Joachim Yahalom; Steven Horwitz
Journal:  Leuk Lymphoma       Date:  2020-08-26

Review 5.  Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Authors:  Paola Ghione; Alison J Moskowitz; Nadia E K De Paola; Steven M Horwitz; Marco Ruella
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 6.  Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.

Authors:  Kamel Laribi; Mustapha Alani; Catherine Truong; Alix Baugier de Materre
Journal:  Oncologist       Date:  2018-04-19

7.  The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma.

Authors:  Zhenchang Sun; Wenjuan Wan; Xudong Zhang; Lei Zhang; Xin Li; Ling Li; Xinhua Wang; Feifei Nan; Hui Yu; Yu Chang; Jiaqin Yan; Zhaoming Li; Fangfang Cui; Jurui Ge; Yaqin Duo XiaXu; Xia Xu; Xiaorui Fu; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-20       Impact factor: 4.322

8.  Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo.

Authors:  Xingkang He; Xin Yin; Jing Wu; Stina L Wickström; Yanhong Duo; Qiqiao Du; Shuhang Qin; Shuzhong Yao; Xu Jing; Kayoko Hosaka; Jieyu Wu; Lasse D Jensen; Andreas Lundqvist; Alexander I Salter; Lars Bräutigam; Wei Tao; Yuguo Chen; Rolf Kiessling; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-28       Impact factor: 11.205

Review 9.  Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas.

Authors:  Jason Yongsheng Chan; Soon Thye Lim
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

10.  Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.

Authors:  Nurulhuda Mustafa; Adina Huey Fang Nee; Jing Yuan Chooi; Sabrina Hui Min Toh; Tae-Hoon Chung; Viknesvaran Selvarajan; Shuangyi Fan; Siok Bian Ng; Michelle Poon; Esther Chan; Joanne Lee; Yen Lin Chee; Anand D Jeyasekharan; Longen Zhou; Jennifer Yang; Wee Joo Chng
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.